Home » Posts tagged with » Daniel O’Day
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also secured an exclusive option to acquire the remaining stake in Pionyr Immunotherapeutics. As per the agreement, shareholders of the cancer immunotherapy company could be paid an additional $1.47 billion in […]

FDA grants EUA for Gilead’s investigational COVID-19 drug remdesivir

Remdesivir EUA status : The US has officially pushed the use of remdesivir for treating the novel coronavirus with the Food and Drug Administration (FDA) granting emergency use authorization (EUA) to the investigational COVID-19 drug candidate being developed by Gilead Sciences. The EUA lets the antiviral drug candidate to be used for the treatment of […]

Continue reading …
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven

Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been acquired by the US biotech company for $95.50 per share in cash to become the latter’s fully-owned subsidiary. Forty Seven will be delisted from the Nasdaq Global Select Market. The […]

Continue reading …
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, a clinical-stage immuno-oncology company based in California, as per the latest pharma acquisition news. The immuno-oncology company is being acquired by Gilead Sciences for $95.50 per share in cash. Through […]

Continue reading …
Gilead Sciences bags Descovy FDA approval for prevention of HIV infection

Descovy FDA approval : Gilead Sciences’ Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) has been approved by the US Food and Drug Administration for HIV Pre-Exposure Prophylaxis (PrEP) or in other words prevention of HIV infection.. PrEP is defined as an HIV prevention method in which medicine is taken everyday before […]

Continue reading …
Gilead Sciences names Lilly senior VP Christi L. Shaw as Kite CEO

US biopharma company Gilead Sciences has named Christi L. Shaw as the new chief executive officer of its subsidiary Kite, a California-based cell therapy company, which the former acquired for about $11.9 billion in 2017. Christi L. Shaw, who will also become a member of the senior leadership team of Gilead Sciences, is said to […]

Continue reading …